Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
Study participants need to have been self-administering etanercept for greater than or equal to 6 months prior to screening. You will be in this study for about 9 weeks. This includes a 4-week screening period and a 5-week treatment period.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject has diagnosis of RA or PsA and indicated for treatment with etanercept per the current label, based on history.
Subject is willing to self-inject per investigator judgement at screening.
Subject has no known history of tuberculosis.
You may not be if
Latex allergy.
Subject has any active infection (including chronic or localized infections) for which anti-infectives were indicated within 4 weeks prior to first study dose of etanercept.
Subject had prosthetic joint infection within 5 years of screening or native joint infection within 1 year of screening.
Other criteria may apply.
Clareo Health | Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept
